Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:KURA NASDAQ:NAMS NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.49$31.36$19.05▼$32.56$3.86B0.742.62 million shsN/AKURAKura Oncology$10.84+1.5%$10.19$5.45▼$12.49$962.27M0.351.59 million shs518,786 shsNAMSNewAmsterdam Pharma$31.09+4.8%$33.30$21.14▼$42.21$3.64B0.081.02 million shs598,081 shsRLAYRelay Therapeutics$19.86+3.5%$16.08$3.03▼$20.79$3.80B1.673.36 million shs620,713 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%+0.03%+0.35%+22.82%+49.74%KURAKura Oncology-1.66%-2.11%+7.55%+12.78%+67.92%NAMSNewAmsterdam Pharma-6.34%-10.85%-0.54%-8.65%+33.65%RLAYRelay Therapeutics-3.67%+2.40%+20.78%+14.17%+448.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.49$31.36$19.05▼$32.56$3.86B0.742.62 million shsN/AKURAKura Oncology$10.84+1.5%$10.19$5.45▼$12.49$962.27M0.351.59 million shs518,786 shsNAMSNewAmsterdam Pharma$31.09+4.8%$33.30$21.14▼$42.21$3.64B0.081.02 million shs598,081 shsRLAYRelay Therapeutics$19.86+3.5%$16.08$3.03▼$20.79$3.80B1.673.36 million shs620,713 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%+0.03%+0.35%+22.82%+49.74%KURAKura Oncology-1.66%-2.11%+7.55%+12.78%+67.92%NAMSNewAmsterdam Pharma-6.34%-10.85%-0.54%-8.65%+33.65%RLAYRelay Therapeutics-3.67%+2.40%+20.78%+14.17%+448.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.001.62% UpsideKURAKura Oncology 2.69Moderate Buy$25.46134.89% UpsideNAMSNewAmsterdam Pharma 2.86Moderate Buy$49.4258.95% UpsideRLAYRelay Therapeutics 3.00Buy$24.9225.48% UpsideCurrent Analyst Ratings BreakdownLatest KURA, CPRX, RLAY, and NAMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026RLAYRelay Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $31.007/20/2026NAMSNewAmsterdam Pharma BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$58.007/20/2026NAMSNewAmsterdam Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.007/17/2026KURAKura Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026RLAYRelay Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.007/16/2026RLAYRelay Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.007/8/2026RLAYRelay Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$28.007/6/2026RLAYRelay Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/30/2026NAMSNewAmsterdam Pharma Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$47.00 ➝ $51.006/15/2026KURAKura Oncology Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$596.96M6.46$2.92 per share10.77$7.76 per share4.06KURAKura Oncology$67.48M14.26N/AN/A$2.00 per share5.42NAMSNewAmsterdam Pharma$22.50M161.52N/AN/A$5.97 per share5.21RLAYRelay Therapeutics$15.35M247.84N/AN/A$3.27 per share6.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.7418.1010.220.9637.08%35.76%31.31%8/5/2026 (Estimated)KURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)Latest KURA, CPRX, RLAY, and NAMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026KURAKura Oncology-$0.89N/AN/AN/A$20.16 millionN/A8/6/2026Q2 2026RLAYRelay Therapeutics-$0.41N/AN/AN/A$0.96 millionN/A8/5/2026Q2 2026CPRXCatalyst Pharmaceuticals$0.48N/AN/AN/A$155.79 millionN/A8/5/2026Q2 2026NAMSNewAmsterdam Pharma-$0.48N/AN/AN/A$1.79 millionN/A5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A7.106.84KURAKura Oncology0.096.156.14NAMSNewAmsterdam PharmaN/A9.769.76RLAYRelay TherapeuticsN/A22.1322.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%KURAKura OncologyN/ANAMSNewAmsterdam Pharma89.89%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%KURAKura Oncology7.60%NAMSNewAmsterdam Pharma12.74%RLAYRelay Therapeutics5.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.42 million109.69 millionOptionableKURAKura Oncology13088.77 million82.03 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableKURA, CPRX, RLAY, and NAMS HeadlinesRecent News About These CompaniesRelay Therapeutics (NASDAQ:RLAY) Research Coverage Started at Canaccord Genuity GroupJuly 19 at 1:43 AM | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Raised to "Strong-Buy" at Canaccord Genuity GroupJuly 17, 2026 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Buy" from BrokeragesJuly 15, 2026 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Buy" by AnalystsJuly 15, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 7.4% - Here's What HappenedJuly 13, 2026 | marketbeat.comSanjiv Patel Sells 48,199 Shares of Relay Therapeutics (NASDAQ:RLAY) StockJuly 10, 2026 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $162,028.60 in StockJuly 9, 2026 | insidertrades.comRelay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 8,660 Shares of StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) CEO Sells $943,736.42 in StockJuly 8, 2026 | marketbeat.comInsider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 50,000 Shares of StockJuly 3, 2026 | insidertrades.comRelay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past YearJune 29, 2026 | fool.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells 93,456 Shares of StockJune 25, 2026 | insidertrades.comRelay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is WhyJune 11, 2026 | insidermonkey.comRelay Therapeutics Expands Authorized Shares at 2026 MeetingJune 9, 2026 | tipranks.comRelay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3, 2026 | seekingalpha.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 27, 2026 | globenewswire.comRelay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - SlideshowMay 22, 2026 | seekingalpha.comRelay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data ReleaseMay 22, 2026 | finance.yahoo.comRelay Therapeutics prices $275M public offering of common stock at $12/shareMay 21, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 20263 Nuclear Stocks for Investors Willing to Wait Out the DipBy Bridget Bennett | July 20, 2026KURA, CPRX, RLAY, and NAMS Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.49 0.00 (0.00%) As of 07/16/2026Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Kura Oncology NASDAQ:KURA$10.84 +0.16 (+1.50%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.NewAmsterdam Pharma NASDAQ:NAMS$31.09 +1.42 (+4.78%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Relay Therapeutics NASDAQ:RLAY$19.86 +0.68 (+3.53%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
